Public Health Bulletin on HIV and STIs in Auvergne-Rhône-Alpes. December 2021.

Published on 1 December 2021

Key points

Decline in participation in the LaboVIH survey in 2020 in Auvergne-Rhône-Alpes as well as nationally, due to the health crisis. Participation in LaboVIH and the accurate reporting of new HIV diagnoses via e-DO by clinicians and laboratory professionals are essential for the production of reliable surveillance indicators.
Decrease in HIV testing in Auvergne-Rhône-Alpes in 2020 (serology tests, rapid diagnostic tests, sales of HIV self-tests), particularly during the first lockdown in spring 2020.
Decrease in the number of new HIV diagnoses between 2017 and 2020: a rate of 39 per million inhabitants in 2020, close to the rate in metropolitan France excluding the Île-de-France region. In 2020, there was an increase in the proportion of men, those over 50, infections among MSM born in France, and people diagnosed at an advanced stage.
The number of AIDS diagnoses remained generally stable, estimated at 10 per million inhabitants in 2020.
Good use of e-DO in the region, especially by clinicians, but some laboratory components are still missing.

Decrease in the number of people tested in private laboratories for gonococcal infections, syphilis, and Chlamydia trachomatis infections in 2020, both in Auvergne-Rhône-Alpes and nationally. The majority of people tested for these three STIs are women.
Decrease in the number of Chlamydia trachomatis infection diagnoses in 2020, both in Auvergne-Rhône-Alpes and nationwide.